机构：[1]Cardiology Department, The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China,[2]Endocrine Department, The Second Affiliated Hospital of Nanchang University, Nanchang, China,[3]Anesthesiology Department, The Second Affiliated Hospital of Nanchang University, Nanchang, China,[4]Department of Pharmacology and Systems Physiology, University of Cincinnati College of Medicine, Cincinnati, OH, United States,[5]Department of Cardiology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China,中山大学附属第一医院[6]Cardiology Department, The Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China,中山大学附属第二医院[7]Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou, China
Background: Epidemiological studies have shown that atrial fibrillation (AF) is a potential cardiovascular complication of coronavirus disease 2019 (COVID-19). We aimed to perform a systematic review and meta-analysis to clarify the prevalence and clinical impact of AF and new-onset AF in patients with COVID-19.<br></p> <br></p> Methods: PubMed, Embase, the Cochrane Library, and MedRxiv up to February 27, 2021, were searched to identify studies that reported the prevalence and clinical impact of AF and new-onset AF in patients with COVID-19. The study was registered with PROSPERO (CRD42021238423).<br></p> <br></p> Results: Nineteen eligible studies were included with a total of 21,653 hospitalized patients. The pooled prevalence of AF was 11% in patients with COVID-19. Older (& GE;60 years of age) patients with COVID-19 had a nearly 2.5-fold higher prevalence of AF than younger (< 60 years of age) patients with COVID-19 (13 vs. 5%). Europeans had the highest prevalence of AF (15%), followed by Americans (11%), Asians (6%), and Africans (2%). The prevalence of AF in patients with severe COVID-19 was 6-fold higher than in patients with non-severe COVID-19 (19 vs. 3%). Furthermore, AF (OR: 2.98, 95% CI: 1.91 to 4.66) and new-onset AF (OR: 2.32, 95% CI: 1.60 to 3.37) were significantly associated with an increased risk of all-cause mortality among patients with COVID-19.<br></p> <br></p> Conclusion: AF is quite common among hospitalized patients with COVID-19, particularly among older (& GE;60 years of age) patients with COVID-19 and patients with severe COVID-19. Moreover, AF and new-onset AF were independently associated with an increased risk of all-cause mortality among hospitalized patients with COVID-19.</p>
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81760050, 81760048, 82100347]; Jiangxi Provincial Natural Science Foundation for Youth Scientific Research [20192ACBL21037]; Young Teachers' Basic Scientific Research Business Expenses Project [20ykpy72]; China Postdoctoral Science FoundationChina Postdoctoral Science Foundation [2020M673016]; China National Postdoctoral Program for Innovative Talents [BX20200400]
第一作者机构：[1]Cardiology Department, The Affiliated Hospital of Jiangxi University of Chinese Medicine, Nanchang, China,
共同第一作者：
通讯作者：
通讯机构：[6]Cardiology Department, The Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Guangzhou, China,[7]Guangdong Province Key Laboratory of Arrhythmia and Electrophysiology, Guangzhou, China
推荐引用方式(GB/T 7714)：
Zuwei Li,Wen Shao,Jing Zhang,et al.Prevalence of Atrial Fibrillation and Associated Mortality Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis[J].FRONTIERS IN CARDIOVASCULAR MEDICINE.2021,8:doi:10.3389/fcvm.2021.720129.
APA：
Zuwei Li,Wen Shao,Jing Zhang,Jianyong Ma,Shanshan Huang...&Xiao Liu.(2021).Prevalence of Atrial Fibrillation and Associated Mortality Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis.FRONTIERS IN CARDIOVASCULAR MEDICINE,8,
MLA：
Zuwei Li,et al."Prevalence of Atrial Fibrillation and Associated Mortality Among Hospitalized Patients With COVID-19: A Systematic Review and Meta-Analysis".FRONTIERS IN CARDIOVASCULAR MEDICINE 8.(2021)
